Watchlist Price Alert

Vera Therapeutics Inc. (VERA)

NASDAQ: VERA · Real-Time Price · USD

24.00

0.35 (1.48%)

At close: Jul 03, 2025, 1:23 PM

23.87

-0.54%

After-hours: Jul 03, 2025, 04:58 PM EDT

1.48% (1D)

Bid	17.1
Market Cap	1.53B
Revenue (ttm)	n/a
Net Income (ttm)	-175.46M
EPS (ttm)	-3
PE Ratio (ttm)	-8
Forward PE	-6.94
Analyst	Buy

Ask	30.34
Volume	629,758
Avg. Volume (20D)	1,822,921
Open	23.75
Previous Close	23.65
Day's Range	23.44 - 24.26
52-Week Range	18.53 - 51.61
Beta	1.13

About VERA

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol VERA

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for VERA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

1 month ago

+67.49%

Vera Therapeutics shares are trading higher after ... Unlock content with Pro Subscription

5 months ago

-6.08%

Vera Therapeutics shares are trading lower. The company announced an exclusive license agreement with Stanford University for VT-109.

News

3 weeks ago · marketbeat.com

Analysts Can't Get Enough of These Little-Known Biopharma Stocks

The biopharmaceuticals industry is both exciting and risky for investors. Many leading growth stocks in the U.S. market are found in this sector, due to the significant rallies that biopharmaceutical ...

1 month ago · benzinga.com

Kidney Health-Focused Vera Therapeutics Stock Price Spikes On Heels Of Successful Trial Data

Vera Therapeutics, Inc. VERA saw its share price surge over 65% during the pre-market trading session on Monday after the company released ORIGIN Phase 3 trial data.

1 month ago · reuters.com

Vera shares skyrocket as kidney disease drug succeeds in late-stage trial

Shares of Vera Therapeutics soared 82% on Monday, after the company said its experimental drug helped significantly reduce excess levels of harmful proteins in the urine of kidney disease patients in ...

1 month ago · seekingalpha.com

Vera Therapeutics: Huge Catalyst Upcoming For Kidney Disease Drug

I am maintaining my 'Hold' rating on Vera Therapeutics from January 2024 despite initial strong stock gains and positive Phase 2b data for atacicept, before a collapse in stock value. In my last note,...